Search clinical trials for: CISH Checkpoint

Total 4868 results

Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Italy, Malaysia, United States, Netherlands, Turkey, France, Germany
Molecular Templates, Inc.

Recruiting

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Cullinan Therapeutics Inc.

Recruiting

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid Tumors

Australia, United States, Canada
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Isala

Recruiting

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie (MINUTE)

Oncology | Infusion Reaction

Netherlands
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Diwakar Davar
Merck Sharp & Dohme LLC; Gateway for Cancer Research

Not yet recruiting

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

PD-1 Refractory Advanced Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC; G1 Therapeutics, Inc.

Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)

Metastatic Triple-Negative Breast Cancer

United States
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Institut Mutualiste Montsouris
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside (VICKI)

Renal Cell Carcinoma | Cancer | Bladder Cancer | MSI-H Cancer

France
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Georgetown University
Bristol-Myers Squibb; Targovax ASA; Janssen, LP

Recruiting

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX)

Pancreatic Ductal Adenocarcinoma | Refractory Non-Small Cell Lung Cancer

United States
Eastern Hepatobiliary Surgery Hospital

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer

China
The Netherlands Cancer Institute

Not yet recruiting

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt)

Metastatic Microsatellite-stable Colorectal Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
AdventHealth Translational Research Institute

Recruiting

Exercise to Boost Response to Checkpoint Blockade Immunotherapy (EX-BOOST)

Merkel Cell Carcinoma | Cutaneous Melanoma | Cutaneous Squamous Cell Carcinoma

United States
Alliance for Clinical Trials in Oncology

Not yet recruiting

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
University of Alabama at Birmingham

Recruiting

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC)

Renal Cell Carcinoma

United States
Institut Mutualiste Montsouris
Institut Curie

Recruiting

Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors (TILT)

Cancer | Immune Checkpoint Inhibitor | Cardiovascular Biomarkers

France
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Tang-Du Hospital

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent

China
Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Cancer Prevention Research Institute of Texas

Recruiting

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma

United States
Ralph G Zinner
Bristol-Myers Squibb

Recruiting

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Lung Cancer, Nonsmall Cell | Lung Cancer Stage III

United States
Lithuanian University of Health Sciences
Research Council of Lithuania

Recruiting

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer (LUCACRIMUNO)

Lung Cancer Stage IV

Lithuania
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Colorectal Cancer

United States
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Xencor, Inc.

Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Recruiting

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma (SCC)

United States
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Asan Medical Center
Seoul National University Hospital; Hanyang University; Soon Chun Hyang University

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV

Korea, Republic of
Energenx Medical LTD.

Recruiting

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NSCLC

China
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

Metastatic Non-small Cell Lung Cancer

Spain, Italy, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, Germany, Argentina, United States, Brazil, India, Japan, France, Taiwan, Thailand, Turkey, Mexico, Hungary, China, Poland, Austria, South Africa, Czechia, Slo... and more
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Second... and other collaborators

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
PharmaEngine

Not yet recruiting

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

Healthy Participants

United States
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
Fudan University

Recruiting

Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer

Gastric Cancer | Chemotherapy Effect | Immune Checkpoint Inhibitor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC (HNC-SYSU-002)

Oral Cancer | HNSCC | PD-1

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States

Search clinical trials for: CISH Checkpoint

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations